SPC/PIL of the products can differ from this general indication.
Abciximab is indicated in adults as an adjunct to heparin and acetylsalicylic acid for:
1. Percutaneous coronary intervention
The prevention of ischemic cardiac complications in patients undergoing percutaneous coronary intervention (balloon angioplasty, atherectomy and stent)
2. Unstable angina
The short-term (1-month) reduction of the risk of myocardial infarction, in patients with unstable angina, not responding to full conventional therapy who have been scheduled for percutaneous coronary intervention.
North AmericaCanada (0)
Bosnia and Herzegovina (0)